|

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

RECRUITINGPhase 1Sponsored by BioAtla, Inc.
Actively Recruiting
PhasePhase 1
SponsorBioAtla, Inc.
Started2023-07-14
Est. completion2028-09-15
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations9 sites
View on ClinicalTrials.gov →

NCT05808634

Summary

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
* Age ≥ 18 years
* Adequate renal function
* Adequate liver function
* Adequate hematological function
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

* Patients must not have clinically significant cardiac disease.
* Patients must not have known non-controlled CNS metastasis.
* Patients must not have active autoimmune disease or a documented history of autoimmune disease.
* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
* Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
* Patients must not be women who are pregnant or breast feeding.

Conditions2

Advanced AdenocarcinomaCancer

Locations9 sites

UC Irvine
Irvine, California, 92697
Chao Family Comprehensive Cancer Center877-827-8839ucstudy@hs.uci.edu
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Lorraine Martinez Seng323-865-3000Lorraine.Martinez@med.usc.edu
Yale Cancer Center
New Haven, Connecticut, 06511
Ingrid Palma203-833-1034ingrid.palma@yale.edu
Northwestern University
Chicago, Illinois, 60611
Clinical Research Office312-695-1301cancer@northwestern.edu
University of Illinois
Chicago, Illinois, 60612
Omer Qazi312-413-1069omerqazi@uic.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.